U.S. FDA Warning Poses Threat to Dr. Reddy's Revenue OutlookBy
Analysts cut FY17 sales estimate by an average 5 bln rupees
Warning increases chance of import alert: Morgan Stanley
Dr. Reddy’s Laboratories Ltd., India’s second-largest drugmaker, could see its sales come under pressure as it faces scrutiny from the U.S. Food and Drug Administration over manufacturing practices at its factories.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.